## Contents

**Preface** *XXIII*
**List of Contributors** *XXV*

**Part One Biochemistry and Molecular Genetics of Drug Metabolism** *1*

**1 Drug-Metabolizing Enzymes – An Overview** *3*
*Pavel Anzenbacher and Eva Anzenbacherová*
1.1 Introduction: Fate of a Drug in the Human Body *3*
1.2 Classification Systems of Drug-Metabolizing Enzymes According to Different Criteria *4*
1.3 Overview of the Most Important Drug-Metabolizing Enzymes *6*
1.3.1 CYPs *6*
1.3.2 Peroxidases *8*
1.3.3 Flavin Monooxygenases *10*
1.3.4 Other Oxidases: Amine Oxidases, and Molybdenum-Containing XO and AO *11*
1.3.5 NADPH Oxidase, NAD(P)H Oxidoreductase, and Dihydropyridine Dehydrogenase *13*
1.3.6 Reductases *14*
1.3.7 Conjugating Enzymes *15*
Acknowledgments *20*
References *20*

**2 Cytochromes P450** *27*
*F. Peter Guengerich*
2.1 Introduction and Historical Perspective *27*
2.2 Nomenclature and Gene Organization *29*
2.3 Regulation *32*
2.3.1 Transcriptional Regulation *32*
2.3.2 Post-Translational and Epigenetic Regulation *34*
2.3.3 Post-Translational Regulation *34*

2.4 Polymorphisms *35*
2.5 Protein Structure *37*
2.6 Catalytic Mechanisms *40*
2.7 What Determines P450 Catalytic Selectivity? *45*
2.8 Oxidative Stress and P450s *47*
2.9 Relevance in Drug Metabolism and Clinical Medicine *48*
References *53*

**3 UDP-Glucuronosyltransferases** *67*
*Christian P. Strassburg and Sandra Kalthoff*
3.1 Introduction *67*
3.2 A Simple Phenotype: Unconjugated Nonhemolytic Hyperbilirubinemia and Glucuronidation *67*
3.3 Organization of UGTs and the *UGT1A* Gene Locus *68*
3.4 *UGT1A* Gene Nomenclature *70*
3.5 Human *UGT1A* Gene Locus and Sequence Variability *71*
3.6 Glucuronidation of Bilirubin *78*
3.7 *UGT1A1* Gene *79*
3.8 Is There an Advantage or Risk Associated with *UGT1A1* Variability? *80*
3.9 *UGT1A1* Gene and Pharmacogenetic Protection *82*
3.9.1 Cardiovascular Disease *82*
3.9.2 Cancer *82*
3.10 *UGT1A1* Gene and Pharmacogenetic Risks *83*
3.10.1 Disposition to Drug Toxicity *83*
3.10.1.1 Irinotecan Toxicity *83*
3.10.1.2 Jaundice in Protease Inhibitor Therapy (Atazanavir and Indinavir) *86*
3.11 *UGT1A1* Variability and Cancer Risk *86*
3.11.1 CRC *87*
3.11.2 Breast Cancer *87*
3.12 *UGT1A3* Gene *87*
3.13 *UGT1A7* Gene *88*
3.13.1 CRC *93*
3.13.2 HCC *93*
3.13.3 Pancreatic Cancer *94*
3.14 Transcriptional Regulation of *UGT1A* Genes *95*
3.15 Aryl Hydrocarbon Receptor/Aryl Hydrocarbon Receptor Nuclear Translocator Regulation of *UGT1A* Genes *95*
3.16 Regulation by Hepatic Nuclear Factors *97*
3.17 Regulation by the Farnesoid X Receptor *97*
3.18 Regulation by Nuclear Factor Erythroid 2-Related Factor 2 *98*
3.19 Regulation by Splice Variants *98*
3.20 Animal Models to Study *UGT1A* Genes *99*
3.21 Outlook *100*

Acknowledgments *101*
References *101*

**4 Sulfotransferases** *117*
*Michael W. H. Coughtrie*
4.1 Introduction *117*
4.2 Background *118*
4.3 PAPS Synthesis *119*
4.4 SULT Enzyme Family *121*
4.4.1 SULT1 Family *121*
4.4.2 SULT2 Family *126*
4.4.3 SULT3, 4, 5 and 6 Families *127*
4.5 Assays for SULT Activity *128*
4.6 Structure and Function of SULT *128*
4.7 SULT Pharmacogenetics *132*
4.8 Bioactivation and the Role of SULTs in Toxicology *133*
4.9 Conclusions and Future Perspectives *135*
References *135*

**5 Glutathione *S*-Transferases** *147*
*Miroslav Dostalek and Anna-Katarina Stark*
5.1 Introduction and History *147*
5.2 Nomenclature, Structure, and Function *148*
5.2.1 Cytosolic GSTs *148*
5.2.1.1 GSTA, GSTM, and GSTP Classes *149*
5.2.1.2 GSTS Class *149*
5.2.1.3 GSTT Class *149*
5.2.1.4 GSTO Class *150*
5.2.1.5 GSTZ Class *150*
5.2.2 Mitochondrial GSTs *150*
5.2.3 Microsomal GSTs *150*
5.3 Substrates *151*
5.4 Regulation, Induction, and Inhibition *151*
5.5 Gene Polymorphism of GSTs *155*
5.5.1 GSTA Polymorphism *156*
5.5.2 GSTM Polymorphism *156*
5.5.3 GSTT Polymorphism *156*
5.5.4 GSTP1 Polymorphism *157*
5.5.5 GSTO Polymorphism *157*
References *157*

**6 Hydrolytic Enzymes** *165*
*Bingfang Yan*
6.1 Carboxylesterases *165*
6.1.1 Overview *165*

6.1.2 Classification and Structural Features *166*
6.1.2.1 Human Carboxylesterases *166*
6.1.2.2 Salient Features of Carboxylesterases *167*
6.1.2.3 Secondary and Crystal Structure *167*
6.1.3 Catalytic Mechanism, Substrate Specificity, and Activators and Inhibitors *168*
6.1.3.1 Catalytic Mechanism *168*
6.1.3.2 Substrate Specificity *169*
6.1.3.3 Activators and Inhibitors *170*
6.1.4 Pharmacogenomics of Carboxylesterases *172*
6.1.4.1 Polymorphisms *173*
6.1.4.2 Interaction with the Cytochrome P450 Enzyme System *173*
6.1.4.3 Interaction with UDP-Glucuronosyltransferases *174*
6.1.4.4 Interactions with Drug Transporters *175*
6.1.4.5 Drug–Insecticide Interactions *175*
6.1.5 Comparison between Human and Animal Carboxylesterases *175*
6.1.5.1 Tissue Distribution *176*
6.1.5.2 Species-Specific Hydrolysis *176*
6.1.5.3 Ontogenic Expression *177*
6.1.5.4 Regulated Expression *177*
6.2 Epoxide Hydrolases *178*
6.2.1 Overview *178*
6.2.2 Classification and Structural Features *179*
6.2.3 Catalytic Mechanisms *180*
6.2.4 Comparison among Various EHs *181*
6.3 Paraoxonases *183*
6.3.1 Overview *183*
6.3.2 Classification and Structural Features *184*
6.3.3 Catalytic Mechanism *185*
6.4 Other Hydrolases *188*
6.4.1 Carbonic Anhydrases *188*
6.4.2 Cholinesterases *188*
6.4.3 β-Glucuronidase *189*
6.4.4 Lipases *190*
6.4.5 Peptidases/Proteases *190*
6.4.6 Valacylovirase *190*
References *191*

**7 Transporting Systems** *199*
*Anne T. Nies, Claudia Resch, and Tadashi Namisaki*
7.1 Introduction *199*
7.2 Classification of Drug Transporters and Transport Mechanisms *199*
7.3 Drug Transporters of the SLC Superfamily *200*
7.4 ABC Drug Transporters *208*

7.5 Drug Transporters and Disease *208*
7.6 Drug Transporters and Pharmacokinetics *212*
7.6.1 Intestinal Transporters *212*
7.6.2 Hepatic Transporters *213*
7.6.3 Renal Transporters *213*
7.6.4 Transporters at the Blood–Brain Barrier *214*
7.7 Role of Drug Transporters in Chemotherapy Resistance *214*
7.8 Pharmacogenomics of Drug Transporters: Implications for Clinical Drug Response *215*
Acknowledgments *215*
References *216*

**8 Transcriptional Regulation of Human Drug-Metabolizing Cytochrome P450 Enzymes** *223*
*Zdenek Dvorak*
8.1 Factors Affecting Drug-Metabolizing Cytochromes P450 *223*
8.1.1 Genetic Polymorphism *223*
8.1.2 Physiological and Pathophysiological Factors *224*
8.1.3 Environmental Factors *224*
8.2 Transcriptional Regulation of CYP *224*
8.2.1 Xenoreceptors, and Steroid and Nuclear Receptors *225*
8.2.1.1 Aryl Hydrocarbon Receptor *225*
8.2.1.2 Pregnane X Receptor *226*
8.2.1.3 Constitutive Androstane Receptor *226*
8.2.1.4 Steroid and Nuclear Receptors *227*
8.2.2 Transcriptional Mechanisms *227*
8.2.2.1 Direct Binding to the Gene Promoter *227*
8.2.2.2 Indirect Binding to the Gene Promoter *227*
8.2.2.3 Regulating the Regulator *228*
8.2.3 Receptor Cross-Talk *228*
8.2.3.1 Ligand Sharing *228*
8.2.3.2 Response Element Sharing *228*
8.2.3.3 Receptor Cascade *228*
8.2.3.4 Coactivator Sharing *229*
8.2.3.5 Metabolic Cross-Talk *229*
8.2.4 Ligands – Agonists and Antagonists *229*
8.3 Regulation of Drug-Metabolizing CYPs *230*
8.3.1 CYP1A Subfamily *230*
8.3.2 CYP1B1 *232*
8.3.3 CYP2A6 *233*
8.3.4 CYP2B6 *234*
8.3.5 CYP2C Subfamily *235*
8.3.6 CYP3A Subfamily *236*
Acknowledgments *238*
References *238*

**9 Importance of Pharmacogenomics** *259*
*Ulrich M. Zanger, Kathrin Klein, and Jessica Rieger*
9.1 Introduction *259*
9.2 Pharmacogenetic Polymorphisms *260*
9.2.1 Lessons from Early Examples *260*
9.2.2 Cytochrome P450 Polymorphisms *263*
9.2.3 Polymorphisms in Further Drug-Metabolizing Enzymes *268*
9.2.4 Polymorphic Drug Transporters *269*
9.3 Polygenic and Multifactorial Aspects of Drug Metabolism Phenotype *270*
9.3.1 Polygenic Inheritance: CYP1A2 and CYP3A4 Conundrums *270*
9.3.2 Epigenetic Influences on Drug Metabolism *272*
9.4 Genomics Technologies and Approaches *273*
9.4.1 GWAS–A Matured Tool in Pharmacogenomics *274*
9.4.2 Genetical Genomics: Identifying Novel Polymorphic ADME Genes *275*
9.5 Conclusions *276*
References *276*

**Part Two Metabolism of Drugs** *285*

**10 Introduction to Drug Metabolism** *287*
*Ulrich M. Zanger*
10.1 Introduction *287*
10.2 Historical Aspects *287*
10.3 Diversity of Drug Metabolic Pathways *288*
10.4 Influence of Drug Metabolism on Pharmacological Activity *289*
10.5 Biotoxification *290*
10.6 Extrahepatic Drug Metabolism *290*
10.7 Factors Affecting Drug Metabolism Activity *291*
10.7.1 Genetic Polymorphism *291*
10.7.2 Sex *292*
10.7.3 Age *293*
10.7.4 Influence of Diseases and Pathophysiological Factors *294*
10.7.5 Environmental Influences *294*
10.8 Conclusions *296*
References *296*

**11 Central Nervous System Drugs** *301*
*Pierre Baumann and Christoph Hiemke*
11.1 Introduction *301*
11.2 Antidepressants *301*
11.2.1 Tricyclic Antidepressants and Structurally Related Compounds *302*
11.2.2 SSRIs *303*
11.2.3 Other Recent Antidepressants *305*

11.2.4 MAO Inhibitors *306*
11.3 Antipsychotics *306*
11.3.1 Phenothiazines and Thioxanthenes *306*
11.3.2 Butyrophenones and Related Compounds *307*
11.3.3 Atypical Antipsychotics *307*
11.4 Tranquillizers and Hypnotic Agents *309*
11.5 Psychostimulants *311*
11.6 Anticonvulsants and Mood Stabilizers *311*
11.7 Agents for Dementia and Cognitive Enhancers *313*
11.8 Antimigraine Drugs *313*
11.9 Other Drugs *314*
11.10 Conclusions *314*
References *315*

**12 Cardiovascular Drugs** *331*
*Stephan Riedmaier and Ulrich M. Zanger*
12.1 Introduction *331*
12.2 RAAS as a Target for Angiotensin-Converting Enzyme Inhibitors and $AT_1$ Receptor Blockers *331*
12.2.1 ACE Inhibitors *332*
12.2.2 ARBs *334*
12.3 Adrenergic Receptor Agonists *337*
12.3.1 $\alpha_1$-Selective Adrenergic Receptor Agonists *337*
12.3.2 $\alpha_2$-Selective Adrenergic Receptor Agonists *338*
12.3.3 β-Selective Adrenergic Receptor Agonists *339*
12.4 Adrenergic Receptor Antagonists *339*
12.4.1 $\alpha_1$-Selective Adrenergic Receptor Antagonists *339*
12.4.2 $\alpha_2$-Selective Adrenergic Receptor Antagonists *340*
12.4.3 β-Selective Adrenergic Receptor Antagonists *342*
12.5 Diuretics *342*
12.5.1 Carbonic Anhydrase Inhibitors *344*
12.5.2 Osmotic Diuretics *344*
12.5.3 $Na^+$–$K^+$–$2Cl^-$ Symport Inhibitors *345*
12.5.4 Thiazide or Thiazide-Like Diuretics *345*
12.5.5 Nonspecific Cation Channel Inhibitors *347*
12.5.6 Inhibitors of Renal Epithelial $Na^+$ Channels *347*
12.5.7 Mineralcorticoid Receptor Antagonists *348*
12.6 Antiarrhythmics *349*
12.6.1 Calcium Channel Blockers *349*
12.7 Anticoagulants *351*
12.7.1 Heparin *352*
12.7.2 Vitamin K Antagonists *352*
12.7.3 Antiplatelet Drugs *352*
12.8 Cholesterol-Lowering Drugs *353*
12.8.1 Bile Acid Sequestrants *354*
12.8.2 Cholesterol Uptake Inhibitors *354*

12.8.3 Fibrates *354*
12.8.4 Statins *355*
References *357*

**13 Anticancer Drugs** *365*
*Matthias Schwab, Elke Schaeffeler, and Hiltrud Brauch*
13.1 Introduction *365*
13.2 Alkylating Drugs *365*
13.2.1 Oxazaphosphorine (Cyclophosphamide, Ifosphamide) *365*
13.2.2 Melphalan *366*
13.2.3 Ethyleneimines (Thiotepa) *366*
13.2.4 Busulfan *366*
13.2.5 Methylhydrazines (Procarbazine) *367*
13.3 Platinum-Containing Agents *367*
13.4 Antimetabolites *367*
13.4.1 Folic Acid Antagonist (Methotrexate) *367*
13.4.2 Pyrimidine Analogs (5-Fluorouracil/Capecitabine/Tegafur) *368*
13.4.3 Cytidine Analogs *368*
13.4.3.1 Cytarabine and Gemcitabine *368*
13.4.3.2 Azacitidine and Decitabine *369*
13.4.4 Purine Analogs *369*
13.4.4.1 6-Thiopurine Analogs *369*
13.4.4.2 Fludarabine Phosphate *370*
13.5 Natural Products *370*
13.5.1 Vinca Alkaloids (Vincristine) *370*
13.5.2 Taxanes (Paclitaxel, Docetaxel) *370*
13.5.3 Camptothecin Analogs *371*
13.5.3.1 Topotecan *371*
13.5.3.2 Irinotecan *371*
13.5.4 Antibiotics *371*
13.5.4.1 Dactinomycin *371*
13.5.4.2 Anthracyclines *372*
13.5.4.3 Epipodophyllotoxins *372*
13.6 Endocrine Therapy *372*
13.6.1 Selective Estrogen Receptor Modulator (Tamoxifen) *372*
13.6.2 Aromatase Inhibitors *373*
13.7 Histone Deacetylase Inhibitor (Vorinostat) *373*
13.8 Tyrosine Kinase Inhibitors *373*
13.9 Proteasome Inhibitor (Bortezomib) *374*
References *374*

**14 Antimicrobial Agents** *379*
*Chantal Csajka, Oscar Marchetti, Oriol Manuel, Laurent Decosterd, and Amalio Telenti*
14.1 Introduction *379*

14.2 Pharmacokinetics/Pharmacodynamics of the Main Families of Antimicrobial Agents *380*
14.2.1 Aminoglycosides *380*
14.2.2 Vancomycin *382*
14.2.3 β-Lactams *383*
14.2.4 Antifungal Agents *386*
14.2.5 Antiviral Agents (Non-HIV) *389*
14.2.5.1 Drugs for Herpes Virus Infection *390*
14.2.5.2 Drugs for Viral Hepatitis *390*
14.2.5.3 Drugs against Respiratory Viruses *391*
14.2.6 Anti-HIV Agents *391*
14.3 Pharmacogenetics *393*
14.4 Conclusions *397*
Acknowledgments *398*
References *398*

**15 Drugs against Acute and Chronic Pain** *403*
*Andrew A. Somogyi and Janet K. Coller*
15.1 Introduction *403*
15.2 Acute Pain *403*
15.2.1 Dexmedotomidine *403*
15.2.2 Paracetamol/Acetaminophen *407*
15.2.3 Nonsteroidal Anti-Inflammatory Drugs *408*
15.2.3.1 Diclofenac *408*
15.2.3.2 Flurbiprofen *408*
15.2.3.3 Ibuprofen *408*
15.2.3.4 Ketoprofen *409*
15.2.3.5 Ketorolac *409*
15.2.3.6 Meloxicam *409*
15.2.3.7 Naproxen *409*
15.2.4 Cyclooxygenase-2 Selective Inhibitors *410*
15.2.4.1 Celecoxib *410*
15.2.4.2 Etoricoxib *410*
15.2.4.3 Parecoxib *410*
15.3 Chronic Pain *410*
15.3.1 Tricyclic Antidepressants *410*
15.3.1.1 Amitriptyline *410*
15.3.1.2 Nortriptyline *411*
15.3.1.3 Imipramine *411*
15.3.1.4 Desipramine *412*
15.3.2 SNRIs *412*
15.3.2.1 Duloxetine *412*
15.3.2.2 Venlafaxine *412*
15.3.3 SSRIs *413*
15.3.3.1 Citalopram *413*

15.3.3.2 Fluoxetine *413*
15.3.3.3 Paroxetine *414*
15.3.4 Ketamine *414*
15.3.5 Antiepileptics *415*
15.3.5.1 Carbamazepine *415*
15.3.5.2 Valproate *415*
15.3.6 Miscellaneous *415*
15.3.6.1 Gabapentin *415*
15.3.6.2 Pregabalin *415*
15.3.6.3 Tapentadol *415*
15.3.7 Opioids *416*
15.3.7.1 Buprenorphine *416*
15.3.7.2 Butorphanol *416*
15.3.7.3 Codeine *416*
15.3.7.4 Dextromoramide *417*
15.3.7.5 Dextropropoxyphene *417*
15.3.7.6 Dihydrocodeine *417*
15.3.7.7 Alfentanil, Fentanyl, Sufentanil, and Remifentanil *417*
15.3.7.8 Heroin (Diamorphine (3,6-Diacetylmorphine)) *417*
15.3.7.9 Hydrocodone *418*
15.3.7.10 Hydromorphone *418*
15.3.7.11 Ketobemidone *418*
15.3.7.12 L-α-Acetylmethadol *418*
15.3.7.13 Levorphanol *418*
15.3.7.14 Loperamide *418*
15.3.7.15 Methadone *419*
15.3.7.16 Morphine *419*
15.3.7.17 Nalbuphine *419*
15.3.7.18 Nicomorphine (3,6-Dinicotionylmorphine) *419*
15.3.7.19 Oxycodone *420*
15.3.7.20 Oxymorphone *420*
15.3.7.21 Pentazocine *420*
15.3.7.22 Pethidine *420*
15.3.7.23 Piritramide *420*
15.3.7.24 Tilidine *420*
15.3.7.25 Tramadol *421*
References *421*

**16 Drugs of Abuse (Including Designer Drugs)** *429*
*Markus R. Meyer and Hans H. Maurer*
16.1 Introduction *429*
16.2 Classic Drugs of Abuse *432*
16.2.1 Morphine and Heroin *432*
16.2.2 Cocaine *432*
16.2.3 THC *433*

16.2.4 Amphetamine/Methamphetamine *434*
16.2.5 LSD *434*
16.2.6 PCP *434*
16.3 Designer Drugs of Abuse *435*
16.3.1 Amphetamine Derivatives *435*
16.3.1.1 Methylenedioxyamphetamines *435*
16.3.1.2 *p*-Substituted Amphetamines *437*
16.3.1.3 2,5-Dimethoxyamphetamines *438*
16.3.2 Phenethylamines (2Cs) *439*
16.3.2.1 2C-B *439*
16.3.2.2 2C-I *440*
16.3.2.3 2C-D *440*
16.3.2.4 2C-E *440*
16.3.2.5 2C-T-2 *440*
16.3.2.6 2C-T-7 *441*
16.3.2.7 Enzymes Involved in the Metabolism of 2,5-Dimethoxyamphetamines *441*
16.3.3 Cathinones *441*
16.3.3.1 Methylone *441*
16.3.3.2 Butylone *442*
16.3.3.3 Ethylone *442*
16.3.3.4 Mephedrone *442*
16.3.4 Phencyclidine Derivatives *443*
16.3.4.1 *N*-(1-Phenylcyclohexyl)-3-ethoxypropylamine (PCEPA) and *N*-(1-Phenylcyclohexyl)-3-methoxypropanamine (PCMPA) *443*
16.3.4.2 *N*-(1-Phenylcyclohexyl)propanamine (PCPr) *443*
16.3.4.3 *N*-(1-Phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and *N*-(1-Phenylcyclohexyl)-2-methoxyethanamine (PCMEA) *444*
16.3.4.4 Enzymes Involved in the Metabolism of Phencyclidine Derivatives *444*
16.3.5 Piperazines *444*
16.3.5.1 N-BZP *445*
16.3.5.2 1-(3,4-Methylenedioxybenzyl)piperazine (MDBP) *445*
16.3.5.3 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) *445*
16.3.5.4 1-(3-Chlorophenyl)piperazine (mCPP) *446*
16.3.5.5 1-(4-Methoxyphenyl)piperazine (MeOPP) *446*
16.3.6 Pyrrolidinophenones *446*
16.3.6.1 α-Pyrrolidinopropiophenone (PPP) *447*
16.3.6.2 4′-Methoxy-α-pyrrolidinopropiophenone (MOPPP) *447*
16.3.6.3 Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) *447*
16.3.6.4 4′-Methyl-α-pyrrolidinopropiophenone (MPPP) *448*
16.3.6.5 4′-Methyl-α-pyrrolidinohexanophenone (MPHP) *448*
16.3.6.6 4′-Methyl-α-pyrrolidinobutyrophenone (MPBP) *449*
16.3.6.7 4′-Methyl-α-pyrrolidinovalerophenone (PVP) *449*

16.3.6.8 3′,4′-Methylenedioxypyrovalerone (MDPV) *449*
16.3.7 Tryptamines *450*
16.3.7.1 5-Methoxy-diisopropyl-tryptamine (5-MeO-DIPT) *450*
References *450*

**17 Nicotine Metabolism and its Implications** *465*
*Andy Z.X. Zhu and Rachel F. Tyndale*
17.1 Introduction *465*
17.2 Absorption and Distribution of Nicotine *465*
17.2.1 Absorption *465*
17.2.2 Distribution *466*
17.3 Excretion of Nicotine *466*
17.4 Metabolism of Nicotine *468*
17.4.1 Primary Metabolites of Nicotine *468*
17.4.2 Secondary Metabolites of Nicotine *470*
17.4.3 Tertiary Metabolite of Nicotine *470*
17.5 Sources of Variation in Nicotine Metabolism *471*
17.5.1 Genetic *471*
17.5.1.1 CYP2A6 and Nicotine *C*-Oxidation *471*
17.5.1.2 Using the 3′-Hydroxycotinine : Cotinine Ratio as an *In Vivo* Probe for CYP2A6 Activity *471*
17.5.1.3 Interethnic Variability in Nicotine *C*-Oxidation *476*
17.5.1.4 Genetic Influences on Other Nicotine-Metabolizing Enzymes *476*
17.5.2 Gender and Pregnancy *477*
17.5.3 Age *478*
17.5.4 Meals and the Chronopharmacokinetics of Nicotine *479*
17.5.5 Xenobiotics *479*
17.5.6 Smoking *480*
17.5.7 Menthol *480*
17.5.8 Other Factors *480*
17.6 Implications of Variation in Nicotine Metabolism and CYP2A6 Activity *481*
17.6.1 Variation in Nicotine Metabolism is Associated with Altered Smoking Behaviors *481*
17.6.2 Variation in Nicotine Metabolism May Alter the Health Consequences of Smoking *481*
17.6.3 Variation in Nicotine Metabolism Alters Smoking Cessation Outcomes *482*
17.7 Conclusions *483*
Acknowledgments *483*
References *484*

**18 Metabolism of Alcohol and its Consequences** *493*
*Helmut K. Seitz and Sebastian Mueller*
18.1 Introduction *493*

18.2 Properties and Sources of Ethanol *494*
18.2.1 Chemical Properties of Ethanol *494*
18.2.2 Ethanol Content of Alcoholic Beverages *494*
18.2.3 Ethanol Generation in the Human Body *494*
18.3 Ethanol Absorption and Elimination *495*
18.3.1 Ethanol Absorption and Ethanol Blood Levels *495*
18.3.2 Calculation of Ethanol Elimination Using the Widmark Equation *496*
18.4 Ethanol Metabolism *497*
18.4.1 Ethanol Metabolism via ADH *497*
18.4.2 Gastric FPM of Ethanol *502*
18.4.3 Ethanol Metabolism via the MEOS *504*
18.4.4 Ethanol Metabolism via Catalase *510*
18.4.5 Nonoxidative Metabolism of Ethanol *510*
18.4.6 Acetaldehyde Metabolism via ALDH *510*
Acknowledgments *511*
References *511*

**Part Three Metabolism of Natural Compounds** *517*

**19 Introduction and Overview** *519*
*Michael Murray*
19.1 Introduction *519*
19.1.1 Sources and Functional Importance of Natural Products *519*
19.1.2 Plant Products as Drugs: A Historical Perspective *520*
19.1.3 Considerations with the Use of Natural Products as Drugs *520*
19.1.4 Biotransformation of Natural Products *521*
19.1.5 Classes of Natural Products *521*
19.2 Terpenoids: A Structurally Complex Group of Natural Products *522*
19.2.1 Terpenoid Biosynthesis *522*
19.2.2 Biotransformation of Terpenoids *524*
19.2.2.1 Monoterpenoids *524*
19.2.2.2 Sesquiterpenoids *527*
19.2.2.3 Diterpenoids *528*
19.2.2.4 Triterpenoids *528*
19.2.2.5 Triterpenoids *530*
19.3 Other Classes of Natural Products *531*
19.3.1 Biosynthesis of Polyketides, Shikimates, and Alkaloids *531*
19.3.2 Biotransformation of Important Polyketides, Shikimates, and Alkaloids in Man *532*
19.4 Summary and Conclusions *536*
Acknowledgments *536*
References *536*

**20 Flavonoids** *543*
*Petr Hodek*
20.1 Flavonoids – Plant Phytochemicals *543*
20.1.1 Classification of Flavonoids and Their Physicochemical Properties *543*
20.1.2 Biosynthesis of Flavonoids and Their Biological Function in Plants *545*
20.2 Absorption and Metabolism of Flavonoids *545*
20.2.1 Flavonoid Bioavailability *545*
20.2.2 Metabolism of Flavonoids *547*
20.2.2.1 Intestinal Metabolism *548*
20.2.2.2 Decisive Role of Colonic Microflora *549*
20.2.2.3 Metabolism in Liver *549*
20.2.2.4 Flavonoid Excretion *550*
20.2.3 Overall Flavonoid Fate in Organisms *551*
20.2.3.1 Plasma Levels and Pharmacokinetics of Flavonoids *553*
20.3 Interactions of Flavonoids with Mammalian Proteins with Possible Implications for Drug Metabolism *554*
20.3.1 Plasma Proteins *554*
20.3.2 ATP-Binding Proteins *555*
20.3.2.1 MRPs *555*
20.3.2.2 Kinases *556*
20.3.3 Flavonoid-Binding Receptors *557*
20.3.3.1 Estrogen Receptor *557*
20.3.3.2 GABA-A Receptor *558*
20.3.3.3 Aryl Hydrocarbon Receptor *558*
20.3.4 Redox Enzyme Activity Modulation *559*
20.3.4.1 Xenobiotic-Metabolizing Enzymes *560*
20.3.4.2 LOXs, COXs, and XOs *561*
20.4 Dietary Flavonoids – Health Issues *562*
20.4.1 Antioxidant and Pro-Oxidant Properties *562*
20.4.2 Antiviral, Antibacterial, and Antifungal Agents *563*
20.4.3 Other Biological Activities of Flavonoids *564*
20.4.4 Flavonoids as Nutraceuticals *565*
20.4.4.1 Cytotoxic and Cytoprotective Effects *566*
20.4.5 Flavonoid Interference with the Metabolism of Endo- and Xenobiotics *567*
20.4.5.1 Flavonoid Impact on the Metabolism of Endogenous Compounds *568*
20.4.5.2 Effect of Flavonoids on Carcinogen Activation *568*
20.5 Flavonoid–Drug Interactions *570*
20.6 Conclusion – Double-Edged Sword Properties of Flavonoids *573*
References *574*

**21 St John's Wort (*Hypericum perforatum* L.)** *583*
*Miroslav Dostalek and Anna-Katarina Stark*
21.1 The Name Hypericum *583*

21.2 Chemical Constituents of *Hypericum perforatum* *583*
21.3 Clinical Pharmacology of *H. perforatum* *587*
21.3.1 Antidepressive Activity *587*
21.3.2 Photodynamic Therapy and Cancer *587*
21.3.3 Antiviral Activity *587*
21.3.4 Other Pharmacological Activities *587*
21.4 Pharmacokinetics and Pharmacokinetic Interactions of *H. perforatum* *588*
21.4.1 Phloroglucinols: Hyperforin *588*
21.4.2 Naphthodianthrones: Hypericin and Pseudohypericin *588*
21.4.3 Flavonoids: Rutin and Quercetin *589*
21.5 *In Vitro* Studies *591*
21.6 *In Vivo* Studies *592*
Acknowledgments *592*
References *603*

**22 Food Components and Supplements** *611*
*Alexandr Parlesak*
22.1 Introduction *611*
22.2 Food Contaminants *612*
22.2.1 Polycyclic Aromatic Hydrocarbons and Polycyclic Aromatic Amines *612*
22.2.2 Acrylamide *613*
22.2.3 Nitrosamines *614*
22.2.4 Fungal Toxins *614*
22.3 Vitamins *616*
22.3.1 Vitamin A, Retinoic Acid, and Carotenoids *616*
22.3.2 Vitamin D (Cholecalciferol and Ergocalciferol) *618*
22.3.3 Vitamin E (Tocopherol) *619*
22.3.4 Water-Soluble Vitamins (Thiamine and Riboflavin) *620*
22.4 Macronutrients *620*
22.4.1 Protein *620*
22.4.2 Fatty Acids *621*
22.4.3 Carbohydrates *622*
22.5 Secondary Plant Metabolites *622*
22.5.1 Grapefruit Juice, Naringenin, and Presystemic Drug Clearance by CYP3A4 *622*
22.5.2 Inhibition of Metabolic Activation of Drugs by CYP3A4 *623*
22.5.3 Secondary Plant Metabolites, CYP Modulation, and Intestinal Inflammation *623*
22.5.4 Parallel Consumption of Drugs and Inhibitors of Intestinal Drug Metabolism–Threats and Chances *624*
22.5.5 Glucosinolates and Allylsulfides *625*
22.5.6 Caffeine *626*
22.5.7 Cholesterol *626*

22.6 Probiotics and Prebiotics in the Modulation of Drug Metabolism *628*
References *629*

**Part Four Metabolism of Unnatural Xenobiotics** *637*

**23 Environmental Pollutants** *639*
*Marie Stiborova*
23.1 Introduction – An Overview *639*
23.1.1 Types of Environmental Pollutants *640*
23.2 Overview of Environmental Pollutants *641*
23.2.1 Air Pollutants *641*
23.2.2 Water Pollutants *642*
23.2.3 Soil Pollutants *642*
23.3 Toxic and Hazardous Environmental Pollutants Interacting with Drug Metabolism *642*
23.3.1 Acetaldehyde *642*
23.3.2 Acetonitrile *643*
23.3.3 2-Acetylaminofluorene *643*
23.3.4 Acrolein *643*
23.3.5 Acrylamide *643*
23.3.6 4-Aminobiphenyl *644*
23.3.7 *o*-Anisidine *644*
23.3.8 Acrylonitrile (2-Propenenitrile) *644*
23.3.9 Arsenic and Arsenic Compounds *645*
23.3.10 Asbestos *645*
23.3.11 Antimony Compounds *646*
23.3.12 Benzene *646*
23.3.13 Benzidine *647*
23.3.14 1,3-Butadiene (Vinyl Ethylene) *647*
23.3.15 Cadmium Compounds *647*
23.3.16 Carbon Tetrachloride *648*
23.3.17 Carbon Monoxide *648*
23.3.18 Chloroform *649*
23.3.19 Chloroprene *649*
23.3.20 Cr (VI) Compounds *650*
23.3.21 Cobalt and Cobalt Compounds *650*
23.3.22 1,4-Dichlorobenzene *651*
23.3.23 1,3-Dichloropropene *651*
23.3.24 Dichloromethane *651*
23.3.25 1,1-Dimethylhydrazine *652*
23.3.26 Ethylene Oxide *652*
23.3.27 Formaldehyde *652*
23.3.28 Heptachlor *653*
23.3.29 Hexachlorobenzene *653*

23.3.30 Hydrazine *654*
23.3.31 Lead and Lead Compounds *654*
23.3.32 Lindane (All Isomers) *655*
23.3.33 Mercury Compounds *655*
23.3.34 $NO_x$ *656*
23.3.35 Ozone *656*
23.3.36 Parathion *656*
23.3.37 Phthalates *657*
23.3.38 Polycyclic Aromatic Hydrocarbons *657*
23.3.39 Polychlorinated Biphenyls *658*
23.3.40 Polychlorinated Dioxins and Furans *658*
23.3.41 Styrene and Styrene Oxide *659*
23.3.42 Sulfur Dioxide *659*
23.3.43 Tetrachloroethylene (Tetrachloroethene, Perchloroethylene) *660*
23.3.44 Vinyl Chloride *660*
23.4 Summary *660*
References *661*

**24 Environmental Estrogens** *671*
*Miroslav Machala and Jan Vondráček*
24.1 Introduction *671*
24.2 Estrogen Receptor Signaling Pathways *672*
24.3 Agonistic/Antagonistic Effects of Xenobiotics on ERs *673*
24.4 Effects of EDCs on Biosynthesis and Metabolism of Estrogens *676*
24.5 Case of Polychlorinated Biphenyls *677*
24.6 Conclusions *678*
References *679*

**25 Biotransformation of Insecticides** *685*
*Corie A. Ellison, Alice L. Crane, and James R. Olson*
25.1 Introduction to Insecticides *685*
25.1.1 Organophosphate Insecticides *685*
25.1.2 Carbamate Insecticides *687*
25.1.3 Pyrethroid Insecticides *687*
25.1.4 Organochlorine Insecticides *688*
25.2 Metabolism of Insecticides *688*
25.2.1 Hepatic Phase I Enzymes Involved in Biotransformation of Insecticides *688*
25.2.1.1 Cytochrome P450s *688*
25.2.1.2 Flavin-Containing Monooxygenases *691*
25.2.1.3 Others *692*
25.2.2 Phase II Metabolism of Insecticides *692*
25.3 Extrahepatic Metabolism of Insecticides *693*
25.4 Factors Affecting Metabolism *694*
25.4.1 Route of Exposure *694*

25.4.2 Interaction of Xenobiotics *695*
25.4.3 Impact of Age, Gender, Species, and Pathology *695*
25.4.4 Interindividual Genetic Variability *696*
25.5 Conclusions *697*
Note *697*
References *697*

**Index** *703*